Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III U.S. study of transdermal patch for schizophrenia meets primary endpoint

Feb. 1, 2018

Vertex selects VX-659 and VX-445 to advance into phase III cystic fibrosis triple combination trials

Feb. 1, 2018

Acasti initiates TRILOGY trials of CaPre in patients with severe hypertriglyceridemia

Feb. 1, 2018

Cara Therapeutics begins pivotal phase III study of Korsuva in CKD-associated pruritus

Feb. 1, 2018

Oncolix sponsoring evaluation of Prolanta for other gynecological cancers

Feb. 1, 2018

FDA gives Protalix Biotherapeutics' PRX-102 fast track designation

Feb. 1, 2018

Sage Therapeutics' SAGE-217 improves sleep efficiency and sleep time in model of insomnia

Feb. 1, 2018

Preclinical data presented for adipoRon in cholangiocarcinoma

Feb. 1, 2018

Dermira begins phase IIb study of lebrikizumab in moderate to severe atopic dermatitis

Feb. 1, 2018

First patient treated in phase III study of BeiGene's tislelizumab

Feb. 1, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...